Olmesartan Medoxomil Synthesis via Phase Transfer Catalysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing processes for preparing Olmesartan medoxomil often result in low purity due to high levels of impurities, particularly Olmesartan acid, and involve complex steps that require acidic conditions and multiple isolations.
Innovation Solution
A process involving alkylation of ethyl 4-(1-hydroxy-1-methylethyl)-2-propylimidazole-5-carboxylate with 4-[2-(trityltetrazol-5-yl)phenyl]benzyl bromide using a phase transfer catalyst and base, followed by hydrolysis and esterification to obtain trityl Olmesartan dihydrate, which is then deprotected to yield Olmesartan medoxomil with high purity, using a one-pot method that simplifies intermediate isolation and reduces impurity levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If existing processes for preparing Olmesartan medoxomil are used, then the product can be obtained, but the purity is low due to high levels of impurities particularly Olmesartan acid
Solution Approach 1:
The synthesis process is divided into distinct modular steps: alkylation to form the imidazole intermediate, hydrolysis to generate the carboxylic acid, esterification to form the medoxomil ester, and deprotection to remove the trityl group. Each step is optimized independently with specific catalysts and conditions, allowing impurities to be controlled and minimized at each stage rather than accumulating throughout the process.
Solution Approach 2:
The invention employs parameter optimization including using phase transfer catalysts (tetrabutylammonium bromide, benzyl trimethyl ammonium chloride) to enhance reaction efficiency, controlling pH levels during hydrolysis and deprotection steps, and optimizing solvent systems (DCM, acetone, ethyl acetate) to maximize product purity while minimizing Olmesartan acid impurity formation.
2Ease of manufacture
If existing processes are used, then Olmesartan medoxomil can be prepared, but the process involves complex steps requiring acidic conditions and multiple isolations
Solution Approach 1:
Multiple reaction steps are combined into a one-pot sequential process where the alkylation, hydrolysis, esterification, and deprotection reactions occur in the same reaction vessel without intermediate isolations. This integration eliminates complex workup procedures, reduces solvent usage, and simplifies the overall manufacturing process while maintaining high product purity.
Solution Approach 2:
The synthesis proceeds continuously through four distinct reaction phases within a single operation: initial alkylation forms the intermediate, followed by hydrolysis to generate the acid, then esterification with the medoxomil leaving group, and finally deprotection to yield the pure product. Each reaction seamlessly transitions to the next without interruption or isolation, maintaining continuous productive action throughout the process.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This process achieves high yields with low impurities, specifically reducing Olmesartan acid impurity levels to less than 1% and facilitates easy dissolution for esterification, resulting in high-purity Olmesartan medoxomil with improved solubility and simplified purification steps.
Implementation Method 1
A process involving alkylation of ethyl 4-(1-hydroxy-1-methylethyl)-2-propylimidazole-5-carboxylate with 4-[2-(trityltetrazol-5-yl)phenyl]benzyl bromide using a phase transfer catalyst and base
Implementation Method 2
alkylation of ethyl 4-(1-hydroxy-1-methylethyl)-2-propylimidazole-5-carboxylate with 4-[2-(trityltetrazol-5-yl)phenyl]benzyl bromide using a phase transfer catalyst and base
Implementation Method 3
followed by hydrolysis and esterification to obtain trityl Olmesartan dihydrate
Implementation Method 4
followed by hydrolysis and esterification to obtain trityl Olmesartan dihydrate
Implementation Method 5
which is then deprotected to yield Olmesartan medoxomil with high purity
Data Source
AI summary
The present invention provides a process for the preparation of Olmesartan medoxomil by condensing the ethyl 4-(1-hydroxy-1-methylethyl)-2-propylimidazole-5-carboxylate with 4-[2-(trityl tetrazol-5-yl)phenyl]benzyl bromide to obtain ethyl 4-(1-hydroxy-1-methyl ethyl)-2-propyl-1-{4-[2-(trityl tetrazol-5-yl)phenyl]phenyl}methylimidazole-5-carboxylate and then hydrolyzing ethyl 4-(1-hydroxy-1-methyl ethyl)-2-propyl-1-{4-[2-(trityl tetrazol-5-yl)phenyl]phenyl}methyl imidazole-5-carboxylate to obtain trityl Olmesartan dihydrate followed by reacting trityl Olmesartan dihydrate with 4-chloromethyl-5-methyl-2-oxo-1,3-dioxolene to obtain trityl Olmesartan medoxomil and then deprotecting trityl Olmesartan medoxomil to obtain Olmesartan medoxomil.